3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
4
Gynecologic
3
Gastrointestinal
3
Tumor-Agnostic
2
Thoracic
1
Sarcoma
1
Genitourinary
1
Breast
1
Conditions
Neoplasms
2
Interventions
pembrolizumab
12
Specimen Handling
8
Biopsy
8
Magnetic Resonance Spectroscopy
7
Paclitaxel
6
trastuzumab deruxtecan
4
Fluorouracil
4
Bevacizumab
4
durvalumab
3
Pemetrexed
3
Oxaliplatin
3
Leucovorin
3
Exercise
3
Cetuximab
3
Carboplatin
3
Capecitabine
3
Blood Specimen Collection
3
trametinib
2
olaparib
2
nilotinib
2
dostarlimab
2
cabozantinib
2
X-Rays
2
Temozolomide
2
Standard of Care
2
Radiosurgery
2
Nivolumab
2
Irinotecan
2
Cisplatin
2
zolbetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
dostarlimab
×
Tumor-Agnostic
×
30 days
×
Clear all
NCT06551142
2026-05-22
PanTumor-101
GlaxoSmithKline
Phase 1
Recruiting
845 enrolled
NCT06796907
2026-05-22
BEHOLD-2
GlaxoSmithKline
Phase 1/2
Recruiting
305 enrolled